Irritable Bowel Syndrome Around the Web


The Difference Between Ulcerative Colitis and Crohn’s Disease

Ulcerative colitis, Crohn’s disease…what’s the difference? Is it really that important to know which form of IBD you have? Yes, because the differences are major and could significantly affect treatment decisions. IBD

Ironwood nets $40M to start licensing constipation drug

Ironwood Pharmaceuticals Inc. has secured a $40 million licensing agreement with Spanish pharmaceutical firm Laboratorios Almirall S.A. for European development and commercialization rights of the Cambridge biotech’s treatment of irritable bowel syndrome.

Mass High Tech

Ironwood Will Receive Up To $55 Million in Near Term Payments Including $40 Million Upfront Licensing Fee

Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European rights to develop and commercialize the investigational compound linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and other gastrointestinal conditions. This agreement is a continuation of Ironwood’s strategy to develop and market its products in the United States while forming partnerships to accelerate delivery to patients in other territories.


iPhone Application Estimates Radiation Exposure

A new iPhone application by Mark Baerlocher, MD helps you determine how much radiation you’ve been exposed to already, as well as how much radiation any potential diagnostic tests may expose you to. As patients, it is our responsibility to keep track of the tests we’re undergoing. IBD

Can Your Financial Woes Upset Your Stomach?

The stress of the worldwide financial meltdown is enough to affect just about everyone — either directly or indirectly. We all know someone (or are the someone) who has lost their job, taken a pay cut, or are stuck in their home that is currently worth less than what they paid for it. IBD

If you liked this article, please share.
Share on Facebook0Tweet about this on TwitterShare on Google+0Share on StumbleUpon0Email this to someone

Join the Discussion.

We'd love to hear from you - leave a comment below